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HIV-1 superinfection, the reinfection of a previously infected patient with a second HIV variant, has 
been documented in several prior studies. Previous observations  that increased viral diversity 
is  linked to more rapid disease progression  and that superinfection may increase a patient’s steady 
state viral load suggest that superinfection may accelerate a patient’s progression to AIDS (Sagar et 
al., 2003). However, studies of the repercussions of superinfection on clinical disease progression 
have been limited. In a recent study published in AIDS, Drs. Keshet Ronen and Julie Overbaugh 
(Human Biology Division) and an international team of collaborators from Seattle and Kenya 
demonstrate that superinfection accelerates laboratory based measures of HIV disease but it does 
not significantly impact clinical progression to disease. 
The researchers assembled the largest prospective cohort study of superinfection to date to 
determine the effect of superinfection on disease progression, identifying 21 superinfected patients 
within a cohort of 146 HIV-infected Kenyan women. Interestingly, women that ultimately became 
superinfected initially had a lower viral initial load than singly infected patients (-0.45 log10 copies/mL, 
P=0.05). However, the viral load in superinfected women increased faster (+0.009 
log10 copies/mL/month, P=0.0008), and they also showed a trend toward faster CD4+ lymphocyte 
decline than singly infected individuals (P=0.06). The researchers next evaluated the impact of 
superinfection on an individual’s disease progression. They found a borderline association for higher 
viral loads in patients after superinfection relative to their viral loads pre-superinfection (+0.21 
log10 HIV copies/mL, P=0.09). Despite these changes to laboratory measures of disease 
progression, the researchers did not detect any significant differences in the time to clinical 
progression events including CD4+ counts <200 cells/μL, initiation of antiretroviral therapy, or death. 
"Our findings have implications on two fronts. First, the observation that individuals who went on to 
acquire superinfection had lower viral load in initial infection suggests that properties of their immune 
response, or the virus they were initially infected with, may predispose them to another HIV infection. 
We are now investigating what these predisposing factors are, since they may shed light on how to 
prevent infection. Second, our findings suggest that a second infection leads to increased viral 
replication. We also hope to understand what mediates that, to help us understand the factors that 
determine viral fitness and replication," said Dr. Keshet Ronen. 
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Superinfected women (red) have faster viral load increases over 
time than singly infected women (blue). 
 
